For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of ...

Shanghai scientists have made breakthrough in protein design by leveraging artificial intelligence, establishing the world's ...

Laromestrocel (Lomecel-B™) has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for Alzheimer's disease ...

using biomarkers to identify patients who were in the early stages of Alzheimer’s and most likely to benefit from treatment, saying it was an innovative design that "exemplifies the importance ...

More than 55 million people worldwide live with dementia, which includes Alzheimer's disease and other ... We're excited to innovate across disciplines to design breakthrough therapies with ...

He died of Alzheimer’s in 2019, at the age of 66. “That’s old for our family,” Reiswig said. For years, Reiswig resisted finding out whether he carried the mutation, but he did get tested ...

Study: Human herpesvirus-associated transposable element activation in human aging brains with Alzheimer's disease. Image Credit: Design_Cells / Shutterstock.com A recent study published in ...

A recent study tests a new drug, gantenerumab on people with a genetically inherited form of Alzheimer’s disease. For people with this condition, dementia is almost inevitable. Gantenerumab ...